NLS Pharmaceutics and Kadimastem have announced the initial closing of a $500,000 fundraising effort, part of a larger $1 million initiative aimed at facilitating a proposed merger between the two ...

ZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and ...

(RTTNews) - NLS Pharmaceutics AG (NLSP) and Kadimastem Ltd. (KDST.TA), which announced their plan to form a combined Nasdaq-listed biotechnology company last month, have today introduced a new ...

NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed ...

Mark Egerton, PhD, chief executive officer of Quotient Sciences, shares insights on a new approach to accelerate drug development, which integrates formulation development, real-time adaptive GMP ...

NLS Pharmaceutics (NASDAQ:NLSP) rose in premarket trading on Monday after the company reported a definitive merger agreement with Kadimastem. NLSP (NLSP) stock climbed +57.22% to $5.66 +2.06 premarket ...

Molecular Pharmaceutics is a peer-reviewed scientific journal, published since 2004 by the American Chemical Society. MP is currently indexed in: Chemical Abstracts Service (CAS), SCOPUS, EBSCOhost, ...

ZURICH - NLS Pharmaceutics Ltd. (NASDAQ:NLSP) shareholders have approved the merger with Israeli cell therapy company Kadimastem Ltd. (TASE:KDST), whose stock has surged over 170% year-to-date ...

HUNT VALLEY, Md., March 10, 2015 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a Contract Development Manufacturing Organization (CDMO) based in Hunt Valley, MD, has announced the expansion ...